California biotechnology company signs license option with CWRU, Dartmouth College

case-western-reserve

A private California biotechnology company has signed a two-year option agreement with Case Western Reserve University and Dartmouth College to advance a novel immunotherapy to treat cancer and infectious diseases.

Mosaic ImmunoEngineering Inc. of Novato, Calif., was granted the exclusive right to license the technology for a novel platform that uses virus-like nanoparticles (VLP) to treat and prevent cancer and infectious diseases in humans and for veterinary use, according to a news release.

Click here to read the complete story.

Story excerpt provided by Crain’s Cleveland Business.

Written by Lydia Coutre.

Originally published September 4, 2020.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: